USNA vs. CGC, CRON, MNMD, BTMD, ACB, CDXC, TYRA, DH, AORT, and AVNS
Should you be buying USANA Health Sciences stock or one of its competitors? The main competitors of USANA Health Sciences include Canopy Growth (CGC), Cronos Group (CRON), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), Tyra Biosciences (TYRA), Definitive Healthcare (DH), Artivion (AORT), and Avanos Medical (AVNS). These companies are all part of the "medical" sector.
USANA Health Sciences (NYSE:USNA) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
USANA Health Sciences received 375 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 60.77% of users gave USANA Health Sciences an outperform vote while only 19.80% of users gave Canopy Growth an outperform vote.
USANA Health Sciences has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
USANA Health Sciences has a net margin of 6.93% compared to Canopy Growth's net margin of -326.75%. USANA Health Sciences' return on equity of 13.49% beat Canopy Growth's return on equity.
In the previous week, Canopy Growth had 3 more articles in the media than USANA Health Sciences. MarketBeat recorded 11 mentions for Canopy Growth and 8 mentions for USANA Health Sciences. Canopy Growth's average media sentiment score of 0.67 beat USANA Health Sciences' score of 0.35 indicating that Canopy Growth is being referred to more favorably in the news media.
54.3% of USANA Health Sciences shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 0.3% of USANA Health Sciences shares are held by company insiders. Comparatively, 0.4% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
USANA Health Sciences has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500.
USANA Health Sciences presently has a consensus target price of $48.00, indicating a potential upside of 11.68%. Canopy Growth has a consensus target price of $4.87, indicating a potential downside of 41.51%. Given USANA Health Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe USANA Health Sciences is more favorable than Canopy Growth.
Summary
USANA Health Sciences beats Canopy Growth on 13 of the 18 factors compared between the two stocks.
Get USANA Health Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding USNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
USANA Health Sciences Competitors List
Related Companies and Tools
